Ali Ahmadi became a PhD student at the Atherothrombosis and Vascular Biology laboratory to explore the mechanisms of diseases and create new therapies to meet pressing clinical needs. He is now engaged in medical research, guided by Prof Karlheinz Peter, Dr Ahmed Refaat, Dr Alex Peh, and A/Prof James McFadyen.

In Australia, someone suffers a stroke every fifteen minutes. Stroke is a prevalent cardiovascular issue with a high death rate and significant long-term effects. The only approved pharmacological treatment for ischemic stroke is thrombolytics. While these medications can save lives, they may also trigger an inflammatory response called ischemia-reperfusion injury, for which there are currently no approved treatments. This highlights the critical need for agents that can mitigate inflammation after an ischemic incident. Ali’s project aims to influence these inflammatory pathways through targeted therapeutics to improve ischemic stroke outcomes.